drugset / Trial / NCT03650257
A Large-scale Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96
Phase 2
Unknown
150 enrolled
Cure&Sure Biotech Co., LTD
Beijing Tiantan Hospital · collabShenzhen Second People's Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This trial is to further study the safety and effectiveness of autologous gp96 treatment of glioblastoma on the basis of preliminary work.
Timeline
- Start
- 2019-08-21
- Primary completion
- 2021-08-20
- Completion
- 2024-08-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | vitespen | Vaccine | 25 ug | Subcutaneous |
| Background | Temozolomide | Small molecule | 150 mg/m2 | — |
| Background | Temozolomide | Small molecule | 200 mg/m2 | — |